Applied Therapeutics Inc (NASDAQ: APLT) on Friday, plunged -3.01% from the previous trading day, before settling in for the closing price of $0.37. Within the past 52 weeks, APLT’s price has moved between $0.29 and $10.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 23.30%. With a float of $117.55 million, this company’s outstanding shares have now reached $141.58 million.
Let’s determine the extent of company efficiency that accounts for 35 employees. In terms of profitability, gross margin is 24.15%, operating margin of -41030.19%, and the pretax margin is -16419.25%.
Applied Therapeutics Inc (APLT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Applied Therapeutics Inc is 16.97%, while institutional ownership is 74.93%. The most recent insider transaction that took place on Mar 04 ’25, was worth 4,561. In this transaction Chief Medical Officer of this company sold 10,366 shares at a rate of $0.44, taking the stock ownership to the 890,409 shares. Before that another transaction happened on Mar 04 ’25, when Company’s See Remarks sold 14,502 for $0.44, making the entire transaction worth $6,381. This insider now owns 390,459 shares in total.
Applied Therapeutics Inc (APLT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 23.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 24.56% during the next five years compared to 26.57% growth over the previous five years of trading.
Applied Therapeutics Inc (NASDAQ: APLT) Trading Performance Indicators
Applied Therapeutics Inc (APLT) is currently performing well based on its current performance indicators. A quick ratio of 3.00 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 185.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Applied Therapeutics Inc (APLT)
Looking closely at Applied Therapeutics Inc (NASDAQ: APLT), its last 5-days average volume was 1.3 million, which is a drop from its year-to-date volume of 2.98 million. As of the previous 9 days, the stock’s Stochastic %D was 28.57%. Additionally, its Average True Range was 0.04.
During the past 100 days, Applied Therapeutics Inc’s (APLT) raw stochastic average was set at 14.38%, which indicates a significant increase from 11.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.56% in the past 14 days, which was lower than the 111.64% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3933, while its 200-day Moving Average is $3.0658. However, in the short run, Applied Therapeutics Inc’s stock first resistance to watch stands at $0.3651. Second resistance stands at $0.3761. The third major resistance level sits at $0.3817. If the price goes on to break the first support level at $0.3485, it is likely to go to the next support level at $0.3429. Now, if the price goes above the second support level, the third support stands at $0.3319.
Applied Therapeutics Inc (NASDAQ: APLT) Key Stats
Market capitalization of the company is 50.12 million based on 141,576K outstanding shares. Right now, sales total 460 K and income totals -105,620 K. The company made 0 K in profit during its latest quarter, and 44,010 K in sales during its previous quarter.
